摘要
目的:探讨临床单独及联合检测肿瘤标志物(CEA、AFP、CA19-9、CA125)和血小板(PLT)计数对消化系恶性肿瘤的辅助诊断价值。方法:采用全自动快速免疫分析系统及全自动血细胞分析仪,检测37例消化系恶性肿瘤及31例良性疾病患者的血清CEA、AFP、CA19-9、CA125及PLT值。结果:消化系恶性肿瘤CEA、CA19-9、CA125及PLT值偏高的比率明显高于良性疾病(P<0.01),CEA、CA19-9、CA125及PLT联合检测可提高肿瘤检出的敏感性(81.1%),但除CA125外,与分别单测相比并无统计学意义(P>0.05)。结论:肿瘤标志物及PLT检测有助于发现肿瘤。从费用-效益比考虑,在临床初筛时,肿瘤标志物与PLT联合检测并不优于单独检测。
Objective ：To evaluate the clinical significance of combined/respective serum tumor marker level and platelet number assay in patients with digestive system malignany. Methods ： Serum level of four common tumor markers （ CEA, AFP, CA 19-9 ,CA 125 ） and platelet numbers were measured with automatic tachyphylaxis analytical system and automatic hematocyte analyzer in 37 cases of digestive system malignany and 31 cases of benign digestive diseases. Results：The level of CEA,CA19-9,CA125 and platelet numbers in digestive system maLignany group were significantly higher than that of the benign digestive disease group（ P 〈0.01 ）. Combined CEA,CA19-9 ,CA125 and platelet number assay can increase tumor-detection sensitivity（ 81.1% ）, but there is no statistical difference when compared with respective assay （P 〉0. 05 ）, except in CA125. Conclusion ：Tumor marker and platelet number assay is useful in detecting tumor, but is not necessarily better than respective assay in initial clinical discrimination when cost-efficiency ratio is taken into consideration.
出处
《华北国防医药》
2007年第1期11-13,共3页
Medical Journal of Beijing Military Region
